PTC Therapeutics Falls After CHMP'S Negative Opinion On Its Marketing Authorization Of Translarna
Shares of PTC Therapeutics, Inc. (PTCT) are declining more than 34 percent on Friday morning trade after the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has given a negative opinion to its conditional authorization and full marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.